FDA and CLIA Regulation
Cross-source consensus on FDA and CLIA Regulation from 1 sources and 5 claims.
1 sources · 5 claims
Risks & contraindications
Highlighted claims
- Any test that produces a biological result likely to change an individual's behavior falls under CLIA jurisdiction, requiring laboratory certification or a formal CLIA waiver. — Rapid Antigen Testing as a COVID-19 Public Health Surveillance Tool
- The FDA has no established regulatory pathway for a test whose primary purpose is population-level transmission reduction rather than individual diagnosis. — Rapid Antigen Testing as a COVID-19 Public Health Surveillance Tool
- The July 2020 FDA EUA template for over-the-counter COVID tests required 90% of PCR's molecular sensitivity, effectively disqualifying any truly cheap paper strip. — Rapid Antigen Testing as a COVID-19 Public Health Surveillance Tool
- Companies with viable cheap paper tests face a regulatory catch-22 that prevents legal manufacture at scale. — Rapid Antigen Testing as a COVID-19 Public Health Surveillance Tool
- Requiring electronic reporting of every negative result makes cheap paper strip tests logistically impractical for daily home use at population scale. — Rapid Antigen Testing as a COVID-19 Public Health Surveillance Tool